加载中
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
最新数据
JP¥397
−JP¥6.00 · -1.49%
盘中时间采用JST。市场数据可能有所延迟。
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
日内区间
当前JP¥397
52周区间
当前JP¥397
盘中时间采用JST。市场数据可能有所延迟。
J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis. The company conducts functional and structural analysis of selected SLC transporters to support drug discovery, collaborates with academic institutions, and participates in joint research for new pharmaceutical development. It is preparing for clinical trials and global distribution of its drug candidates. The company was founded in 2005 and is based in Yokohama, Japan.
日内区间
当前JP¥397
52周区间
当前JP¥397
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
